IN BRIEF: Oxford Biomedica subsidiary signs deals with three US firms

Oxford Biomedica PLC- Oxfordshire, England-based gene and cell therapy group - Says subsidiary ...

Alliance News 14 December, 2022 | 10:25AM
Email Form Facebook Twitter LinkedIn RSS

Oxford Biomedica PLC- Oxfordshire, England-based gene and cell therapy group - Says subsidiary Oxford Biomedica Solutions LLC has signed agreements with three unnamed US biotechnology firms. Under the agreements, the subsidiary will provide its full platform offering to support the new partners' pre-clinical gene therapy programmes.

Chief Executive Officer Roch Doliveux says: "Securing four new AAV customers in 2022 exceeds our original stated target of two new customers by the end of 2022. We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations.

Oxford Biomedica Solutions is a high-performing full-scope adeno-associated virus manufacturing and innovation business. Adenoviruses are a group of widely-studied viruses that are not known to cause disease and could be used for gene therapy.

Current stock price: 377.10 pence, down 1.5% on Wednesday morning in London

12-month change: down 64%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Oxford BioMedica PLC 323.50 GBX -2.27 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures